ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2021
29 Avril 2022 - 06:00PM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible)
(Paris:ABNX), a new generation biotech company dedicated to the
discovery and development of innovative therapies for patients,
announces that it has filed with the “Autorité des Marchés
Financiers” (AMF) its Universal Registration Document for the year
ended December 31, 2021, dated April 29, 2022.
ABIONYX Pharma's Universal Registration Document for the
financial year ending December 31, 2021, includes in
particular:
- The annual financial report for 2021, consisting of the
consolidated financial statements, the annual financial statements
and the related statutory auditors' reports;
- The management report;
- The corporate governance report;
- A description of the share buyback program.
This document is available on the company's website
(www.abionyx.com) and on the AMF website (www.amf-France.org). It
is also available at the company's registered office, 33-43 avenue
Georges Pompidou - Building D, Balma, 31130.
The Universal Registration Document has also been published in
European Single Electronic Format (ESEF), with the five tables of
the consolidated financial statements (the primary financial
statements) marked up using the XBRL markup language.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220429005529/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Nicolas Merigeau abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024